Patents by Inventor Andreas Bueltmann

Andreas Bueltmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES TARGETING SPECIFICALLY HUMAN CXCR2
    Publication number: 20160060347
    Abstract: This disclosure generally relates to antibodies or fragments thereof which interact with CXCR2. The disclosure further discloses antibodies, which bind to specific extracellular domains of CXCR2. The disclosure further relates to therapeutics comprising CXCR2-specific antibodies and methods of treatment using CXCR2-specific antibodies or fragments thereof.
    Type: Application
    Filed: April 15, 2014
    Publication date: March 3, 2016
    Inventors: Tanja Herrmann, Andreas Bueltmann
  • Use of EDG2 receptor in an animal model of heart failure
    Patent number: 7169612
    Abstract: Mammals and myocardial mammal cells transformed with G protein coupled receptor EDG2 are presented for use in an animal model for heart failure.
    Type: Grant
    Filed: November 12, 2003
    Date of Patent: January 30, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Evi Kostenis, Paulus Wohlfart, Jochen Huber, Kai Rosport, Andreas Bueltmann, Christine Baumgartner, Götz Muench, Martin Ungerer
  • Use of EDG2 receptor in an animal model of heart failure
    Publication number: 20040132182
    Abstract: Mammals and myocardial mammal cells transformed with G protein coupled receptor EDG2 are presented for use in an animal model for heart failure.
    Type: Application
    Filed: November 12, 2003
    Publication date: July 8, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Evi Kostenis, Paulus Wohlfart, Jochen Huber, Kai Rosport, Andreas Bueltmann, Christine Baumgartner, Gotz Muench, Martin Ungerer